The only things that will move this stock are positive results from human trials. Get it? The rest is hype from a management team unworthy of their positions and their salaries. Keep pumping all they like, but until the IC trial has completed enrollment (over 3 years for 150 patients, pathetic) and the analyses show what we all hope is true, the rest we hear has little significance to the value of the company. We plan to...., shows potential...., have discussed..., may improve..., possible effects..., shows improvement in models..., received patent...etc.. What does all this truly mean when it boils down to the effectiveness of the technology? Show me more than a bunch of preclinical & PH1 trials.
The markets want results, as do I. Enough with the nonsense and move forward, not sideways.
With regards to your statement "there were 110 holders of record". In almost every instance when you buy or sell securities with a broker, your name is "not" actually on the stock or bond certificate. The name that appears on the certificate is that of your broker, and this is referred to as being held "in street name".
DEFINITION of 'In Street Name' A brokerage account where the customer's securities and assets are held under the name of the brokerage firm, "rather than the name of the individual" who purchased the security or asset.
Biggest apprehension is Obama as President. I want as little money in the stock market as possible with this madman as our "leader." I still own 9,500 share but would buy more except for having the worst president ever in the White House.
Zami glommed up 25,500 more and YANAY YAKY another 10,000!!! I hope these guys are right! Allo ~ I'm sorry i scooped the story before you. You were asleep at the wheel.
Pluristem Will Have A PRODUCT In Japan Soon ? And It Will Be Similarly Priced ! Do The Math ! Giddy-Up !
Sentiment: Strong Buy
MESOBLAST’S JAPAN LICENSEE RECEIVES PRICING FOR TEMCELL® HS Inj FOR TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE
Melbourne, Australia; and New York, USA; 26 November 2015: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that its licensee in Japan, JCR Pharmaceuticals Co. Ltd., has received notification that the Japanese Government’s National Health Insurance (NHI) body has formally set the price for the mesenchymal stem cell product TEMCELL® HS Inj., effective from today.
JCR announced that the launch of TEMCELL for the treatment of acute graft versus host disease (aGVHD) after an allogeneic bone marrow transplant (BMT) is anticipated in February 2016. Under its agreement with JCR, Mesoblast is entitled to receive royalties and other payments at pre-defined thresholds of cumulative net sales.
The approved and reimbursed dosing regimen in Japan for TEMCELL is as follows:
• For all patients, eight doses of 2 million cells/kilogram, delivered as an intravenous infusion.
• For patients with persistent symptoms beyond four weeks, a further weekly dose of 2 million cells/kilogram may be given for four additional weeks.
Reimbursement for TEMCELL has been authorized by NHI at ¥868,680 (A$9,767 / US$7,079) per bag of 72 million cells. In Japan, the average adult patient is expected to receive 16 or up to 24 bags of 72 million cells. On this basis, Mesoblast expects a treatment course of TEMCELL in an adult Japanese patient to be reimbursed at ¥13,898,880 (A$156,000 / US$113,000) or up to ¥20,848,320 (A$234,000 / US$170,000).
Mesoblast believes it is well positioned to have the first industrially manufactured allogeneic cell-based product approved in the United States, with its product candidate for the treatment of steroid refractory aGHVD in children.
The Company expects to complete recruitment of its open label, 60-patient Phase 3 trial in children with steroid-refractory aGVHD in the fourth quarter of 2016 and to announce top-line interim results of the trial during the third quarter of 2016. This interim analysis may support a Biologics License Application (BLA) regulatory filing by the end of 2016.
In the US, pricing reimbursement methodology is expected to consider the burden of illness associated with steroid-refractory aGVHD as well as health utilization costs, and may result in a higher price than in Japan. This life-threatening illness is designated as an orphan indication.
According to the Center for International Blood and Marrow Transplant Research, there are approximately 30,000 allogeneic BMTs globally. In the US, there are expected to be 8,900 allogeneic BMTs in 2015, with 25% of all cases in the pediatric population. Of these patients, 50% are expected to develop aGVHD. Liver or gastrointestinal involvement occur in up to 40% of all patients with aGVHD and are associated with the greatest risk of death, with mortality rates of up to 85%. Currently, in the US there are no approved therapies for patients with steroid-refractory aGVHD.
Sentiment: Strong Buy
Allo is absolutly correct Mazeldik this is an enormous and great news for PSTI. It opens the door to a new and very soon partnership/deal in Japan with a prospect for a high return to PSTI.
" authorized by NHI at ¥868,680 (A$9,767 / US$7,079) per bag of 72 million cells".
These numbers are the ones , I believe, PSTI was waiting for in order to negociate the deal value.
WOW, $7000 per dose .
Sentiment: Strong Buy
Yaki paid $2.11 and Zami paid $2.10-$2.12... I guess I'm the smart one since I only paid $2.07 for my 500 shares today 😄
You are mean, you are a bully and you hide behind internet anonymity. I became interested in the stock in large part because of your posts. I now find you to be of insignificant impact. Your lines of Betty Sue and the like are repetitive and only reflect back on you. I would ask that you take the time to do some reflection. For others who may have trusted your input, the recent lack of integrity shows that to be a mistake. The stock market and PSTI are in trouble. The CEO has very little to offer in marketing and I am not sure has the class to ask for help in that area. You do not help the cause of Pluristem with your attitude towards other investors or your lack of reality input.
Trader Vic Posted in part:
'I just looked the analyst recommendations on PSTI ASTM GERN and STEM....All are SELLS..."
If you are new, or if you are older do yourself a favor and look at analyst recommendations on a number of stocks then look at how the stock did until the next "review" and at other times. The very first time I started looking at investing and looking for recommendations from Analysts I was shocked. The "predictions" were wrong 50% of the time. That is a minimum. On many stocks they were wrong 80% of the time. So it is with Pluristem. Look at the price predictions for the past yeas for PSTI. Not good and all wrong.
The market is in a state of "froth" at the moment and it has been for some time. I looked at a number of Biotech stocks and from what I saw, a lot of them were down and most importantly down on good news.
At the moment, Medivation, Celgene and Biotime are all up, Celgene up 4%
Take a look at the Raymond James Recommendations. They appear in an article from 7/30/15 by Gregg Greenberg. The title is "Four Stem-Cell Stocks With Promise"
Now go look at the 1 year and 2 year charts. Biotech stocks are very VERY heaviliy manipulated. Look at the charts. They are a joke compared to blue chips, (I include Apple, Google, Microsoft and Major Medical stocks.
Nothing has really changed in the prospect books for PSTI over the past year with two notable exceptions. The first is that slowly but surely institutional investors are moving into the stock. The second is that more patents have been granted, some of them look huge from a layman's point of view. MDPLANET has consistenly made the observation that nothing really big and long term is going to happen with the stock until we get some positive clinical trials results and move towards the market. I agree.
I do believe that there may be some intermediate plays coming. There is a good chance for a major spike, runup and selloff. I say this because every once in a while PSTI spikes.
yep. Buteo & allo are the same people. BTW, it's not only a 52 weak low, but a 3 year low as well.